(MCK) McKesson - Ratings and Ratios
Pharmaceuticals, Medical-Surgical Supplies, Rx Technology, Distribution
Dividends
| Dividend Yield | 0.38% |
| Yield on Cost 5y | 1.77% |
| Yield CAGR 5y | 12.51% |
| Payout Consistency | 93.2% |
| Payout Ratio | 8.4% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 23.9% |
| Value at Risk 5%th | 36.8% |
| Relative Tail Risk | -6.18% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.15 |
| Alpha | 26.27 |
| CAGR/Max DD | 1.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.256 |
| Beta | 0.107 |
| Beta Downside | -0.132 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.91% |
| Mean DD | 4.20% |
| Median DD | 2.67% |
Description: MCK McKesson December 02, 2025
McKesson Corporation (NYSE:MCK) operates as a full-stack healthcare services and distribution company across four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical arm distributes a broad mix of branded, generic, specialty, biosimilar and OTC drugs while also offering practice-management and clinical-support services to community oncology and other specialty practices. RxTS connects biopharma, payors, pharmacies and providers through technology platforms that enable medication access, price transparency, electronic prior authorization and third-party logistics. Medical-Surgical Solutions supplies and maintains equipment for hospitals, surgery centers, long-term-care and home-health providers. The International segment extends similar distribution, logistics and IT services to pharmacies, hospitals and manufacturers outside the United States.
Key recent metrics (FY 2023): revenue of roughly $251 billion, operating cash flow of $12 billion, and a dividend yield near 2.6 %. The RxTS segment posted double-digit revenue growth (≈12 % YoY) driven by expanding e-prescribing and prior-authorization services, while the Medical-Surgical business grew modestly (~4 % YoY) as hospitals increase spend on procedural supplies post-pandemic. McKesson’s net debt-to-EBITDA ratio sits around 2.2×, indicating a manageable leverage profile.
Primary economic drivers include the aging U.S. population and rising prevalence of chronic disease, which lift overall prescription drug spend, especially in specialty and biosimilar categories. At the sector level, consolidation among pharmacy benefit managers and a shift toward digital health platforms create tailwinds for McKesson’s RxTS solutions, while supply-chain volatility and reimbursement pressure remain downside risks.
For a deeper quantitative view, you may find ValueRay’s analyst toolkit useful for modeling MCK’s cash-flow sensitivities.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (4.03b TTM) > 0 and > 6% of Revenue (6% = 23.23b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 1.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -2.10% (prev -1.64%; Δ -0.46pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 6.87b > Net Income 4.03b (YES >=105%, WARN >=100%) |
| Net Debt (5.68b) to EBITDA (5.88b) ratio: 0.97 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.88 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (124.4m) change vs 12m ago -3.79% (target <= -2.0% for YES) |
| Gross Margin 3.35% (prev 3.82%; Δ -0.47pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 494.4% (prev 455.9%; Δ 38.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 16.82 (EBITDA TTM 5.88b / Interest Expense TTM 235.0m) >= 6 (WARN >= 3) |
Altman Z'' 0.70
| (A) -0.10 = (Total Current Assets 59.89b - Total Current Liabilities 68.03b) / Total Assets 84.16b |
| (B) 0.23 = Retained Earnings (Balance) 19.62b / Total Assets 84.16b |
| (C) 0.05 = EBIT TTM 3.95b / Avg Total Assets 78.29b |
| (D) 0.22 = Book Value of Equity 18.72b / Total Liabilities 84.74b |
| Total Rating: 0.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.29
| 1. Piotroski 6.50pt |
| 2. FCF Yield 5.53% |
| 3. FCF Margin 1.65% |
| 4. Debt/Equity -5.63 |
| 5. Debt/Ebitda 0.97 |
| 6. ROIC - WACC (= 58.88)% |
| 7. RoE -182.0% |
| 8. Rev. Trend 94.98% |
| 9. EPS Trend 83.59% |
What is the price of MCK shares?
Over the past week, the price has changed by -7.51%, over one month by -3.18%, over three months by +17.86% and over the past year by +33.60%.
Is MCK a buy, sell or hold?
- Strong Buy: 10
- Buy: 3
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the MCK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 934.8 | 14.8% |
| Analysts Target Price | 934.8 | 14.8% |
| ValueRay Target Price | 1055.9 | 29.7% |
MCK Fundamental Data Overview November 29, 2025
P/E Trailing = 27.6246
P/E Forward = 22.8833
P/S = 0.284
P/B = 5.0435
P/EG = 1.2098
Beta = 0.388
Revenue TTM = 387.09b USD
EBIT TTM = 3.95b USD
EBITDA TTM = 5.88b USD
Long Term Debt = 6.01b USD (from longTermDebt, last quarter)
Short Term Debt = 2.02b USD (from shortTermDebt, last quarter)
Debt = 9.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 5.68b USD (from netDebt column, last quarter)
Enterprise Value = 115.60b USD (109.92b + Debt 9.79b - CCE 4.11b)
Interest Coverage Ratio = 16.82 (Ebit TTM 3.95b / Interest Expense TTM 235.0m)
FCF Yield = 5.53% (FCF TTM 6.39b / Enterprise Value 115.60b)
FCF Margin = 1.65% (FCF TTM 6.39b / Revenue TTM 387.09b)
Net Margin = 1.04% (Net Income TTM 4.03b / Revenue TTM 387.09b)
Gross Margin = 3.35% ((Revenue TTM 387.09b - Cost of Revenue TTM 374.13b) / Revenue TTM)
Gross Margin QoQ = 3.43% (prev 3.35%)
Tobins Q-Ratio = 1.37 (Enterprise Value 115.60b / Total Assets 84.16b)
Interest Expense / Debt = 0.76% (Interest Expense 74.0m / Debt 9.79b)
Taxrate = 16.63% (232.0m / 1.40b)
NOPAT = 3.30b (EBIT 3.95b * (1 - 16.63%))
Current Ratio = 0.88 (Total Current Assets 59.89b / Total Current Liabilities 68.03b)
Debt / Equity = -5.63 (negative equity) (Debt 9.79b / totalStockholderEquity, last quarter -1.74b)
Debt / EBITDA = 0.97 (Net Debt 5.68b / EBITDA 5.88b)
Debt / FCF = 0.89 (Net Debt 5.68b / FCF TTM 6.39b)
Total Stockholder Equity = -2.22b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.79% (Net Income 4.03b / Total Assets 84.16b)
RoE = -182.0% (negative equity) (Net Income TTM 4.03b / Total Stockholder Equity -2.22b)
RoCE = 104.2% (EBIT 3.95b / Capital Employed (Equity -2.22b + L.T.Debt 6.01b))
RoIC = 64.82% (NOPAT 3.30b / Invested Capital 5.08b)
WACC = 5.94% (E(109.92b)/V(119.71b) * Re(6.41%) + D(9.79b)/V(119.71b) * Rd(0.76%) * (1-Tc(0.17)))
Discount Rate = 6.41% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -3.40%
[DCF Debug] Terminal Value 78.18% ; FCFE base≈5.56b ; Y1≈5.52b ; Y5≈5.77b
Fair Price DCF = 828.4 (DCF Value 102.24b / Shares Outstanding 123.4m; 5y FCF grow -1.46% → 3.0% )
EPS Correlation: 83.59 | EPS CAGR: 13.41% | SUE: 3.56 | # QB: 1
Revenue Correlation: 94.98 | Revenue CAGR: 11.48% | SUE: -0.32 | # QB: 0
EPS current Year (2026-03-31): EPS=38.67 | Chg30d=+0.334 | Revisions Net=+14 | Growth EPS=+17.0% | Growth Revenue=+13.7%
EPS next Year (2027-03-31): EPS=43.81 | Chg30d=+0.433 | Revisions Net=+12 | Growth EPS=+13.3% | Growth Revenue=+8.3%
Additional Sources for MCK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle